Cytek Biosciences Inc (CTKB)
Debt-to-assets ratio
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Long-term debt | US$ in thousands | — | — | — | — | — | — | — | — | — | — | — |
| Total assets | US$ in thousands | 494,457 | 519,430 | 525,054 | 524,575 | 519,476 | 499,295 | 492,817 | 485,879 | 463,305 | 454,320 | 230,279 |
| Debt-to-assets ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
December 31, 2023 calculation
Debt-to-assets ratio = Long-term debt ÷ Total assets
= $—K ÷ $494,457K
= 0.00
Cytek Biosciences Inc has consistently maintained a debt-to-assets ratio of 0.00 across all observed quarters. This indicates that the company has not used debt as a source of financing for its assets during the period under review. The consistent ratio of 0.00 suggests that Cytek Biosciences Inc relies primarily on equity and internal funds to support its operations and investments in assets. This can be seen as a positive indicator of the company's financial stability and low financial risk, as it does not have significant financial obligations in the form of debt. However, it is important to note that while a low or zero debt-to-assets ratio can be favorable, it may also limit the company's ability to leverage debt to potentially enhance returns or pursue certain growth opportunities.
Peer comparison
Dec 31, 2023